Effects of doxofylline on oxidative stress and inflammatory factors in patients with esophageal cancer radical surgery

Objective To investigate the effects of doxofilate on oxidative stress and inflammatory factors in patients with esophageal cancer radical surgery in order to provide a clinical reference for the rational use of doxophylline. Methods Total 80 patients with esophageal cancer radical surgery in our hospital from May, 2014 to June, 2015 were randomly divided into observation group and control group, the patients in both groups were treated with the same amount of saline and Doxofloxacin after intubation of the double-lumen bronchus, the changes of the intraoperative indicators in the two groups were recorded, the levels of oxidative stress and the level of inflammatory factors were compared between the two groups, and the incidence of adverse reactions was observed. Results There was no significant difference in intraoperative indexes (P>0.05); At the time of the T₁ to T₃, the levels of superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) in the two groups were significantly lower than those in the T₀ time (P<0.05), and the malonaldehyde (MDA) level was significantly higher than that of the T₀ (P<0.05), and the levels of SOD and GSH-Px in the observation group were significantly higher than those in the control group (P<0.05), MDA level was significantly lower than that in the control group (P<0.05); At the time of the T₁ to T₃, the levels of tumor necrosis factor (TNF)-α, interleukin (IL-6) and IL-10 in the two groups were significantly higher than those at the T₀ time (P<0.05), the level of IL-10 was significantly higher (P<0.05) and the levels of TNF-α and IL-6 were significantly lower in the observation group as compared with the control group (P<0.05); The incidence of adverse reactions in the observation group was significantly lower than that in the control group (P<0.05). Conclusion Doxofylline can significantly inhibit the oxidative stress response and inflammatory response of the radical patients with esophageal cancer, and reduce the incidence of postoperative adverse reactions, which is worthy of clinical promotion.